Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Neurology
Published in: Current Treatment Options in Neurology 4/2013

01-08-2013 | NEUROLOGIC MANIFESTATIONS OF SYSTEMIC DISEASE (A PRUITT, SECTION EDITOR)

Neurosarcoidosis

Authors: Kenkichi Nozaki, MD, PhD, Marc A. Judson, MD

Published in: Current Treatment Options in Neurology | Issue 4/2013

Login to get access

Opinion statement

Neurosarcoidosis can involve either the central nervous system (CNS), the peripheral nervous system (PNS), or both. The clinical manifestations are varied and include cranial neuropathy, aseptic meningitis, hydrocephalus, headache, seizure, neuropsychiatric symptoms, neuroendocrine dysfunction, myelopathy, and peripheral neuropathy. Neurologic problems that develop in sarcoidosis patients should not be assumed to represent neurosarcoidosis, as they are often attributable to another cause. The diagnostic work up of neurosarcoidosis should include an evaluation for potential extra-neural involvement and histologic confirmation of sarcoidosis. If there is no appropriate extra-neurologic organ for biopsy, a biopsy from involved neural tissue needs to be considered. Biopsy of the dura and leptomeninges is less invasive than biopsy of the brain or spinal cord parenchyma. Gadolinium-enhanced magnetic resonance imaging (MRI) of the brain and spinal cord is the most sensitive test for neurosarcoidosis, while the diagnostic specificity of cerebrospinal fluid (CSF) analysis is limited. Corticosteroids are the mainstay of treatment for neurosarcoidosis. In general, oral corticosteroids are used for mild to moderate cases, while high-dose intravenous methylprednisolone is used in severe cases or refractory cases that fail to respond to oral corticosteroids. Immunomodulating and cytotoxic agents are often required for steroid-refractory neurosarcoidosis or for patients who develop significant corticosteroid adverse effects. Methotrexate is used as a first-line corticosteroid sparing agent. Tumor necrosis factor-alpha inhibitors, including infliximab, are effective for refractory neurosarcoidosis. Cyclophosphamide is also used for refractory neurosarcoidosis patients, but, because of the drug’s significant toxicity, it is usually reserved for severe cases that have failed oral therapies when tumor necrosis factor alpha antagonists cannot be obtained. In addition to anti-granulomatous therapy, treatment is frequently required for neurosarcoidosis-associated conditions, such as epilepsy and neuroendocrine dysfunction. Surgical intervention is indicated for life threatening complications such as hydrocephalus, steroid-refractory spinal cord compression, or mass lesions causing increased intracranial pressure.
Literature
1.
Judson MA. Sarcoidosis: clinical presentation, diagnosis, and approach to treatment. Am J Med Sci. 2008;335(1):26–33.PubMedCrossRef
2.
Chen RC, McLeod JG. Neurological complications of sarcoidosis. Clin Exp Neurol. 1989;26:99–112.PubMed
3.
Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol. 1985;42(9):909–17.PubMedCrossRef
4.
Delaney P. Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med. 1977;87(3):336–45.PubMedCrossRef
5.
Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997;157(16):1864–8.PubMedCrossRef
6.
Gullapalli D, Phillips II LH. Neurosarcoidosis. Curr Neurol Neurosc Rep. 2004;4(6):441–7.CrossRef
7.
Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(2):118–25.PubMed
8.
Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, et al. Neurosarcoidosis: presentations and management. Neurologist. 2010;16(1):2–15.PubMedCrossRef
9.
Brouwer MC, de Gans J, Willemse RB, van de Beek D. Neurological picture. Sarcoidosis presenting with hydrocephalus. J Neurol Neurosurg Psychiatr. 2009;80(5):550–1.PubMedCrossRef
10.
Westhout FD, Linskey ME. Obstructive hydrocephalus and progressive psychosis: rare presentations of neurosarcoidosis. Surg Neurol. 2008;69(3):288–92. discussion 292.PubMedCrossRef
11.
Benzagmout M, Boujraf S, Gongora-Rivera F, Bresson D, Van-Effenterre R. Neurosarcoidosis which manifested as acute hydrocephalus: diagnosis and treatment. Intern Med. 2007;46(18):1601–4.PubMedCrossRef
12.
Varron L, Broussolle C, Candessanche JP, Marignier R, Rousset H, Ninet J, et al. Spinal cord sarcoidosis: report of seven cases. Eur J Neurol. 2009;16(3):289–96.PubMedCrossRef
13.
Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol. 2007;64(5):691–6.PubMedCrossRef
14.
Rudkin AK, Wilcox RA, Slee M, Kupa A, Thyagarajan D. Relapsing encephalopathy with headache: an unusual presentation of isolated intracranial neurosarcoidosis. J Neurol Neurosurg Psychiatr. 2007;78(7):770–1.PubMedCrossRef
15.
Krumholz A, Stern BJ, Stern EG. Clinical implications of seizures in neurosarcoidosis. Arch Neurol. 1991;48(8):842–4.PubMedCrossRef
16.
Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125(3):997–1004.PubMedCrossRef
17.
Chang B, Steimel J, Moller DR, Baughman RP, Judson MA, Yeager Jr H, et al. Depression in sarcoidosis. Am J Resp Crit Care Med. 2001;163(2):329–34.PubMedCrossRef
18.
Porter N, Beynon HL, Randeva HS. Endocrine and reproductive manifestations of sarcoidosis. QJM. 2003;96(8):553–61.PubMedCrossRef
19.
Langrand C, Bihan H, Raverot G, Varron L, Androdias G, Borson-Chazot F, et al. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM. 2012;105(10):981–95.PubMedCrossRef
20.
Vital A, Lagueny A, Ferrer X, Louiset P, Canron MH, Vital C. Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature. Clin Neuropath. 2008;27(2):96–105.
21.
Oldroyd A, Dawson T, Nixon J. A case of neurosarcoidosis that presented with symptoms of Guillain-Barre syndrome. BMJ Case Rep. 2011.
22.•
Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep. 2011;15(3):201–6. This article is a thorough review of small fiber neuropathy in sarcoidosis.PubMedCrossRef
23.
Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Op Pulm Med. 2010;16(5):472–9.CrossRef
24.
Reulen JP, Lansbergen MD, Verstraete E, Spaans F. Comparison of thermal threshold tests to assess small nerve fiber function: limits vs levels. Clin Neurophysiol. 2003;114(3):556–63.PubMedCrossRef
25.
Truini A, Galeotti F, Romaniello A, Virtuoso M, Iannetti GD, Cruccu G. Laser-evoked potentials: normative values. Clin Neurophysiol. 2005;116(4):821–6.PubMedCrossRef
26.
Atherton DD, Facer P, Roberts KM, Misra VP, Chizh BA, Bountra C, et al. Use of the novel Contact Heat Evoked Potential Stimulator (CHEPS) for the assessment of small fiber neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts. BMC Neurol. 2007;7:21.PubMedCrossRef
27.
Low PA, Caskey PE, Tuck RR, Fealey RD, Dyck PJ. Quantitative sudomotor axon reflex test in normal and neuropathic subjects. Ann Neurol. 1983;14(5):573–80.PubMedCrossRef
28.
Ferriby D, de Seze J, Stojkovic T, Hachulla E, Wallaert B, Destee A, et al. Long-term follow-up of neurosarcoidosis. Neurology. 2001;57(5):927–9.PubMedCrossRef
29.
Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatr. 2009;80(3):297–304.PubMedCrossRef
30.
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Resp Crit Care Med. 1999;160(2):736–55.
31.••
Nozaki K, Judson MA. Neurosarcoidosis: clinical manifestations, diagnosis and treatment. Presse Med. 2012;41(6 Pt 2):e331–348. This article provides the most current and comprehensive review of neurosarcoidosis.PubMedCrossRef
32.
Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest. 1997;112(1):220–8.PubMedCrossRef
33.•
Nozaki K, Scott TF, Sohn M, Judson MA. Isolated neurosarcoidosis: case series in 2 sarcoidosis centers. Neurologist. 2012;18(6):373–7. This is the largest case series of isolated neurosarcoidosis.PubMedCrossRef
34.
Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. Am J Radiol. 2004;182(2):289–95.
35.
Pickuth D, Heywang-Kobrunner SH. Neurosarcoidosis: evaluation with MRI. J Neurradiol. 2000;27(3):185–8.
36.•
Sohn M, Culver DA, Judson MA, Scott TF, Tavee J, Nozaki K. Spinal cord neurosarcoidosis. Am J Med Sci. (in press).This case series describes a large number of diverse manifestations of spinal neurosarcoidosis. Class IV evidence.
37.
Tartaglino LM, Friedman DP, Flanders AE, Lublin FD, Knobler RL, Liem M. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology. 1995;195(3):725–32.PubMed
38.
Khoury J, Wellik KE, Demaerschalk BM, Wingerchuk DM. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis. Neurologist. 2009;15(2):108–11.PubMedCrossRef
39.
Dale JC, O’Brien JF. Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc. 1999;74(5):535. Erratum in Mayo Clin Proc. 2000;75(3):318.PubMed
40.
Tahmoush AJ, Amir MS, Connor WW, Farry JK, Didato S, Ulhoa-Cintra A, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):191–7.PubMed
41.
Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest. 2003;124(5):2023–6. Class IV evidence
42.
Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol. 1995;52(9):875–9.PubMedCrossRef
43.
Marangoni S, Argentiero V, Tavolato B. Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol. 2006;253(4):488–95.PubMedCrossRef
44.
Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis–diagnosis and management. QJM. 1999;92(2):103–17.PubMedCrossRef
45.
Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med. 2009;103(2):268–73. Class IV evidence.
46.
47.
Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, et al. Intravenous pulse administration of cyclophosphamide vs daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthr Rheum. 1998;41(10):1835–44. Class II evidence.
48.
Lewis SJ, Ainslie GM, Bateman ED. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Class IV evidence. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(1):87–92.PubMed
49.
Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999;14(5):1117–22. Class IV evidence.
50.
Corbett J. Treating CNS, sarcoidosis with infliximab and mycophenolate mofetil. Curr Neurol Neurosci Rep. 2009;9(5):339–40. Class IV evidence.
51.
Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009;72(4):337–40. Class IV evidence.
52.
Chaussenot A, Bourg V, Chanalet S, Fornari JM, Lebrun C. [Neurosarcoidosis treated with mycophenolate mofetil: two cases]. Rev Neurol (Paris). 2007;163(4):471–5. Class IV evidence.
53.
Androdias G, Maillet D, Marignier R, Pinede L, Confavreux C, Broussolle C, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology. 2011;76(13):1168–72. Class IV evidence.
54.
Santos E, Shaunak S, Renowden SA, Scolding NJ. Treatment of refractory neurosarcoidosis with infliximab. Class IV evidence. J Neurol Neurosurg Psychiatr. 2010;81(3):241–6.PubMedCrossRef
55.
Pereira J, Anderson NE, McAuley D, Bergin P, Kilfoyle D, Fink J. Medically refractory neurosarcoidosis treated with infliximab. Class IV evidence. Intern Med J. 2011;41(4):354–7.PubMedCrossRef
56.
Chintamaneni S, Patel AM, Pegram SB, Patel H, Roppelt H. Dramatic response to infliximab in refractory neurosarcoidosis. Ann Indian Acad Neurol. 2010;13(3):207–10. Class IV evidence.
57.
Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127(3):1064–71. Class IV evidence.
58.
Nozaki K, Silver RM, Stickler DE, Abou-Fayssal NG, Giglio P, Kamen DL, et al. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci. 2011;342(5):352–5.PubMedCrossRef
59.
Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol. 1998;55(9):1248–54. Class IV evidence.
60.
Bihan H, Christozova V, Dumas JL, Jomaa R, Valeyre D, Tazi A, et al. Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine. 2007;86(5):259–68.PubMedCrossRef
61.
Kang S, Suh JH. Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiat Oncol Investig. 1999;7(5):309–12. Class IV evidence.
62.
Menninger MD, Amdur RJ, Marcus Jr RB. Role of radiotherapy in the treatment of neurosarcoidosis. Am J Clin Oncol. 2003;26(4):e115–8. Class IV evidence.
63.
Stelzer KJ, Thomas Jr CR, Berger MS, Spence AM, Shaw CM, Griffin TW. Radiation therapy for sarcoid of the thalamus/posterior third ventricle: case report. Neurosurgery. 1995;36(6):1188–91. Class IV evidence.
Metadata
Title
Neurosarcoidosis
Authors
Kenkichi Nozaki, MD, PhD
Marc A. Judson, MD
Publication date
01-08-2013
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 4/2013
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-013-0242-9

Other articles of this Issue 4/2013

Current Treatment Options in Neurology 4/2013 Go to the issue

IN MEMORIAM

In Memory of Dr. William J. Weiner

MOVEMENT DISORDERS (O SUCHOWERSKY, SECTION EDITOR)

Treatment of Restless Legs Syndrome

NEUROLOGIC MANIFESTATIONS OF SYSTEMIC DISEASE (A PRUITT, SECTION EDITOR)

Nervous System Lyme Disease: Diagnosis and Treatment

MOVEMENT DISORDERS (O SUCHOWERSKY, SECTION EDITOR)

Behavior Therapy for Tourette Syndrome: A Systematic Review and Meta-analysis

EPILEPSY (E WATERHOUSE, SECTION EDITOR)

New Treatment Options for Lennox-Gastaut Syndrome

MOVEMENT DISORDERS (O SUCHOWERSKY, SECTION EDITOR)

Treatment of Huntington Disease